This clinical trial, sponsored by Central South University, investigates the combination of transcatheter arterial chemoembolization (TACE) and PD-1 knockout engineered T cells for the treatment of advanced hepatocellular carcinoma (HCC). The market for HCC therapies is growing due to increasing incidence rates and a lack of effective treatment options for unresectable cases. The innovative approach of combining TACE with genetically modified T cells may provide a competitive edge in the immuno-oncology space, particularly in regions with high HCC prevalence. However, the trial's current status is 'recruiting,' and the overall status remains 'unknown,' indicating potential risks in timelines and regulatory pathways. Diligence should focus on the safety profile and efficacy outcomes as they will significantly influence market entry and adoption.